Disease-modifying drugs in Alzheimer’s disease

References

• Bartus RT Dean RL3rd Beer B Lippa AS The cholinergic hypothesis of geriatric memory dysfunction Science 1982 217 408 414 7046051
   PubMed Web of Science ®Google Scholar
• Perry EK The cholinergic hypothesis ten years on Br Med Bull 1986 42 63 69 3513895
   PubMed Web of Science ®Google Scholar
• Bowen DM Francis PT Pangalos MN Stephens PH Procter AW Treatment strategies for Alzheimer’s disease Lancet 1992 339 132 133 1345865
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ Martino AM Antuono PG Nicotinic acetylcholine binding sites in Alzheimer’s disease Brain Res 1986 371 146 151 3708340
   PubMed Web of Science ®Google Scholar
• Newhouse PA Potter A Levin ED Nicotinic acetylcholine involvement in Alzheimer’s and Parkinson’s disease: implications for therapeutics Drugs Aging 1997 11 206 228 9303280
   PubMed Web of Science ®Google Scholar
• Doody RS Stevens JC Beck C Practice parameter: management of dementia (an evidence-based review) Neurology 2001 56 1154 1166 11342679
   PubMed Web of Science ®Google Scholar
• Inglis F The tolerability and safety of cholinesterase inhibitors in the treatment of dementia Int J Clin Pract Suppl 2002 127 45 63 12139367
   PubMedGoogle Scholar
• Knowles J Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes Core Evid 2006 1 195 219 22500154
   PubMedGoogle Scholar
• Froelich L Gertz HJ Heun R Donepezil for Alzheimer’s disease in clinical practice – the DONALD study Dement Geriatr Cogn Disord 2004 18 37 43 15084792
   PubMed Web of Science ®Google Scholar
• Birks JS Harvey R Donepezil for dementia due to Alzheimer’s disease Cochrane Database Syst Rev 2003 3 CD001190 12917900
   PubMedGoogle Scholar
• Courtney C Farrell D Gray R AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial Lancet 2004 363 2105 2115 15220031
   PubMed Web of Science ®Google Scholar
• Birks J Evans JG Iakovidou V Tsolaki M Rivastigmine for Alzheimer’s disease Cochrane Database Syst Rev 2009 2 CD001191 19370562
   PubMed Web of Science ®Google Scholar
• Cumbo E Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer’s disease: 18-month, randomized, open-label trial Prim Care Community Psychiatr 2005 10 95 102
   Google Scholar
• Pattanaprateep O Phongchareonsuk P Chaikledkaew U The cost-effectiveness of donepezil and rivastigmine in the treatment of Alzheimer’s disease in Thailand private hospital Value Health 2005 8 314 815
   Web of Science ®Google Scholar
• Bullock R Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings Curr Med Res Opin 2005 21 1 10 15881470
   PubMed Web of Science ®Google Scholar
• Bond M Rogers G Peters J The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No 111): a systematic review and economic model Health Technol Assess 2012 16 1 470 22541366
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S Amatniek J Ascher S Sadik K Ramaswamy K Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study Alzheimer Dis Assoc Disord 2005 19 240 245 16327351
   PubMed Web of Science ®Google Scholar
• Farrimond LE Roberts E McShane R Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review BMJ Open 2012 2 e000917
   Web of Science ®Google Scholar
• Clerici F Vanvacore N Elia A Memantine effects on behaviour in moderately severe to severe Alzheimer’s disease: a post-marketing surveillance study Neurol Sci 2012 33 23 31 21584738
   PubMed Web of Science ®Google Scholar
• Qaseem A Snow V Cross TJJr Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians Ann Intern Med 2008 148 370 378 18316755
   PubMed Web of Science ®Google Scholar
• Jones WR Dimebon disappointment Alzheimers Res Ther 2010 2 25 20836898
   PubMed Web of Science ®Google Scholar
• Tayeb HO Yang HD Price BH Tarazi FI Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors Pharmacol Ther 2012 134 8 25 22198801
   PubMed Web of Science ®Google Scholar
• Rafii MS Walsh S Little JT A phase II trial of huperzine A in mild to moderate Alzheimer disease Neurology 2011 76 1389 1394 21502597
   PubMed Web of Science ®Google Scholar
• Salomone S Caraci F Leggio GM New pharmacological strategies for treatment of Alzheimer’s disease: focus on disease-modifying drugs Br J Clin Pharmacol 2012 73 504 517 22035455
   PubMed Web of Science ®Google Scholar
• Weinreb O Amit T Bar-Am O Youdim MB Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer’s disease treatment Curr Drug Targets 2012 13 483 494 22280345
   PubMed Web of Science ®Google Scholar
• Hardy J Akksop D Amyloid hypothesis deposition as the central event in the aetiology of Alzheimer’s disease Trends Pharmacol Sci 1991 12 383 388 1763432
   PubMed Web of Science ®Google Scholar
• Chow VW Mattsonn MP Wong PC Gleichmann M An overview of APP processing enzymes and products Neuromolecular Med 2010 12 1 12 20232515
   PubMed Web of Science ®Google Scholar
• Haass C Selkoe DJ Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide Nat Rev Mol Cell Biol 2007 8 101 112 17245412
   PubMed Web of Science ®Google Scholar
• Watson GS Cholerton BA Reger MA Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study Am J Geriatr Psychiatry 2005 13 950 958 16286438
   PubMed Web of Science ®Google Scholar
• Gold M Alderton C Zvartau-Hind M Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study Dement Geriatr Cogn Disord 2010 30 131 146 20733306
   PubMed Web of Science ®Google Scholar
• Merck An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer’s Disease (P07738) (EPOCH) ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2012 [updated November 4, 2013]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01739348?term=MK-8931&rank=2. NLM identifier: NCT01739348 Accessed November 22, 2013
   Google Scholar
• Merck Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer’s Disease (MK-8931-019) (APECS) ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2013 [updated November 19, 2013]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01953601?term=MK-8931&rank=3. NLM identifier: NCT01953601 Accessed November 22, 2013
   Google Scholar
• Kaether C Haass C Steiner H Assembly, trafficking and function of gamma-secretase Neurodegener Dis 2006 3 275 283 17047368
   PubMed Web of Science ®Google Scholar
• Tomita T Secretase inhibitors and modulators for Alzheimer’s disease treatment Expert Rev Neurother 2009 9 661 679 19402777
   PubMed Web of Science ®Google Scholar
• Bateman RJ Siemers ER Mawuenyega KG A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system Ann Neurol 2009 66 48 54 19360898
   PubMed Web of Science ®Google Scholar
• Schor NF What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us Ann Neurol 2011 69 237 239 21387368
   PubMed Web of Science ®Google Scholar
• Dockens R Wang JS Castaneda L A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects Clin Pharmacokinet 2012 51 681 693 23018531
   PubMed Web of Science ®Google Scholar
• Schenk D Barbour R Dunn W Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 1999 400 173 177 10408445
   PubMed Web of Science ®Google Scholar
• Gilman S Koller M Black RS Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 2005 64 1553 1562 15883316
   PubMed Web of Science ®Google Scholar
• Holmes C Boche D Wilkinson D Long-term effect of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 2008 372 216 223 18640458
   PubMed Web of Science ®Google Scholar
• Winblad B Andreasen N Minthon L Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurol 2012 11 597 604 22677258
   PubMed Web of Science ®Google Scholar
• Galimberti D Ghezzi L Scarpini E Immunotherapy against amyloid pathology in Alzheimer’s disease J Neurol Sci 2013 333 50 54 23299047
   PubMed Web of Science ®Google Scholar
• Khorassani F Hilas O Bapineuzumab, an investigational agent for Alzheimer’s disease P T 2013 38 89 91 23599675
   PubMedGoogle Scholar
• Moreth J Mavoungou C Schindowski K Passive anti-amyloid immunotherapy in Alzheimer’s disease: what are the most promising targets? Immun Ageing 2013 10 18 23663286
   PubMed Web of Science ®Google Scholar
• Tariot PN Schneider LS Cummings J Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 68 853 861 21810649
   PubMed Web of Science ®Google Scholar
• Forlenza OV Diniz BS Radanovic M Santos FS Talib LL Gattaz WF Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial Br J Psychiatry 2011 198 351 356 21525519
   PubMed Web of Science ®Google Scholar
• Luna-Medina R Cortes-Canteli M Sanchez-Galiano S NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders J Neurosci 2007 27 5766 5776 17522320
   PubMed Web of Science ®Google Scholar
• Mangialasche F Solomon A Winblad B Mecocci P Kivipelto M Alzheimer’s disease: clinical trials and drug development Lancet Neurol 2010 9 702 716 20610346
   PubMed Web of Science ®Google Scholar
• Morimoto BH Schmechel D Hirman J A phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment Dement Geriatr Cogn Disord 2013 35 325 336 23594991
   PubMed Web of Science ®Google Scholar
• Green KN Steffan JS Martinez-Coria H Nicotinamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau J Neurosci 2008 28 11500 11510 18987186
   PubMed Web of Science ®Google Scholar